Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Tanogitran (BIBT 986 BS) in Healthy Male Subjects
NCT02254057Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2002
- Primary completion
- Oct 2002
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in thromboembolic disorders comparing Tanogitran (Rising Dose) with Placebo (2 arms). Primary endpoints: Area under the concentration-time curve from 0 to infinity up to 48 hours, Area under the concentration-time curve from 0 to last quantifiable concentration up to 48 hours and 16 more. Started Jul 2002; status: completed.
02
Drugs
tanogitran
03
Conditions
thromboembolic disorders
Beyond the preview
Go deeper on NCT02254057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254057.